keyword
https://read.qxmd.com/read/38528354/are-the-glim-criteria-guiding-in-the-course-of-hematological-malignancies
#1
JOURNAL ARTICLE
F Yilmaz, M R Aras, Hba Ozturk, H N Sahin, A K Gunes, M Albayrak
BACKGROUND: Different degrees of malnutrition are seen in patients with hematological malignancies. None of the approaches used to determine malnutrition risk have general acceptance. The use of the GLIM criteria developed by the Global Leadership Initiative on Malnutrition has promising results. MATERIALS AND METHODS: A total of 67 patients with leukemia, lymphoma, and multiple myeloma were included in the study. NRS-2002 (Nutritional Risk Screening-2002) was used to screen the nutritional status of the patients, and malnutrition was diagnosed and graded using the GLIM criteria in patients who were found to be at risk of malnutrition in this test...
March 1, 2024: Nigerian Journal of Clinical Practice
https://read.qxmd.com/read/38527834/-clinical-features-and-risk-factors-for-invasive-fungal-sinusitis-after-allogeneic-hematopoietic-stem-cell-transplantation
#2
JOURNAL ARTICLE
H X Fu, J J Li, Y Y Zhang, Y Q Sun, X D Mo, T T Han, J Kong, M Lyu, W Han, H Chen, Y Y Chen, F R Wang, C H Yan, Y Chen, J Z Wang, Y Wang, L P Xu, X J Huang, X H Zhang
Objective: To analyze the clinical characteristics and outcomes of patients with invasive fungal sinusitis (invasive fungal rhinosinusitis, IFR) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and explored the risk factors for IFR after allo-HSCT. Methods: Nineteen patients with IFR after allo-HSCT at Peking University People's Hospital from January 2012 to December 2021 were selected as the study group, and 95 patients without IFR after allo-HSCT during this period were randomly selected as the control group (1:5 ratio) ...
January 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38521640/financial-toxicity-time-toxicity-and-quality-of-life-in-multiple-myeloma
#3
JOURNAL ARTICLE
Rahul Banerjee, Andrew J Cowan, Marivel Ortega, Constance Missimer, Paul A Carpenter, Masumi Ueda Oshima, Rachel B Salit, Phuong T Vo, Catherine J Lee, Rohtesh S Mehta, Nicole M Kuderer, Veena Shankaran, Stephanie J Lee, Christopher T Su
BACKGROUND: Patients with multiple myeloma (MM) may be on therapy for years, which can lead to financial toxicity (FinTox) or time toxicity (TimeTox). The prevalence, predictors, and quality of life (QOL) impacts of FinTox and TimeTox during different phases of MM treatment have not been characterized. PATIENTS AND METHODS: We conducted a single-center cross-sectional survey of patients with MM who had undergone transplantation. FinTox+ was defined as a COST-FACIT score <23, TimeTox+ as MM-related interactions (including phone calls) ≥1x weekly or ≥1x monthly in-person among far-residing patients, QOL using PROMIS Global Health, and functional status using patient-reported Karnofsky performance status (KPS)...
February 23, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38521639/dampening-logistics-creating-inequitable-access-a-major-threat-despite-advancements
#4
JOURNAL ARTICLE
Fathima Shehnaz Ayoobkhan, Al-Ola Abdallah, Faiz Anwer, Nausheen Ahmed
No abstract text is available yet for this article.
February 22, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38519329/recent-developments-in-convenience-of-administration-of-the-anti-cd38-antibody-isatuximab-subcutaneous-delivery-and-fast-intravenous-infusion-in-patients-with-multiple-myeloma
#5
REVIEW
Hang Quach, Gurdeep Parmar, Maria-Victoria Mateos, Sikander Ailawadhi, Xavier Leleu
Isatuximab-based combinations are among the accepted standard-of-care regimens for early-line treatment of patients with relapsed/refractory multiple myeloma (RRMM), based on the results of the Phase 3 ICARIA-MM and IKEMA trials. Further study findings have shown benefit with Isa-based combinations in patients with newly diagnosed MM, as reported from the randomized GMMG-HD7 and CONCEPT trials. Isa is currently approved in various countries for intravenous (IV) administration in patients with RRMM. A more convenient route of administration, such as subcutaneous (SC) injection, and faster IV infusion may substantially increase convenience of treatment...
February 12, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38518400/second-generation-al-18-f-labeled-d-amino-acid-peptide-for-cxcr4-targeted-molecular-imaging
#6
JOURNAL ARTICLE
Muriel Aline Spahn, Kaat Luyten, Tom Van Loy, Mike Sathekge, Christophe M Deroose, Michel Koole, Dominique Schols, Wim Vanduffel, Kristof De Vos, Pieter Annaert, Guy Bormans, Frederik Cleeren
BACKGROUND: The C-X-C chemokine receptor type 4 (CXCR4) is overexpressed in many cancers, e.g. multiple myeloma and acute leukemia, yet solely [68 Ga]PentixaFor is used for clinical PET imaging. The aim of this study was to develop and assess a second generation Al18 F-labeled D-amino acid peptide based on the viral macrophage inflammatory protein II for CXCR4 targeted molecular imaging. METHODS: We designed a library of monomer and multimer constructs and evaluated their binding affinity for human and mouse CXCR4...
March 19, 2024: Nuclear Medicine and Biology
https://read.qxmd.com/read/38516380/il-2-cd25-axis-mediates-cellular-networks-promoting-the-growth-of-cd25-acute-myeloid-leukemia-cells
#7
JOURNAL ARTICLE
Kazunori Nakase, Kenkichi Kita
Although the expression of interleukin-2 receptor α-chain (IL-2Rα, CD25) has been provided prognostic significance independent of known biomarkers in acute myeloid leukemia (AML), the functional role of CD25 molecule remains unknown. Since IL-2 can be trans-presented via CD25 to another cell, CD25+ AML cells may deliver environmental IL-2 to surrounding immune cells to produce myeloid growth factors for their proliferation. We hypothesize that cellular interactions via IL-2/CD25 axis in the bone marrow microenvironment contributes to the growth advantage of these AML cells and affects the clinical outcome of those AML patients...
2024: Leukemia Research Reports
https://read.qxmd.com/read/38516379/efficacy-and-safety-of-different-chemotherapy-regimens-combined-with-thalidomide-in-the-treatment-of-diagnosed-hiv-associated-diffuse-large-b-cell-lymphoma
#8
REVIEW
Peng Fei Tao, Chuan Qian, Qi Wen Zhou, Sen Lin, Dan Qing Wang, Xi Wang, Shi Fen Chen, Hai Yan Min
OBJECTIVE: To investigate the short-term efficacy and safety of different chemotherapy regimens combined with thalidomide, in the treatment of low-income patients with newly diagnosed HIV-associated diffuse large B-cell lymphoma. METHODS: A retrospective analysis was performed on 42 patients with HIV-DLBCL who were admitted to the Infectious Diseases Department of Yunnan Provincial Infectious Diseases Hospital from January 2018 to December 2020. 14 cases (including 1 case in stage II and 13 cases in stage III/IV) were treated with R-CHOP, 24 cases (including 1 case in stage II and 23 cases in stage III/IV) were treated with R-DAEPOCH, and 4 cases (including 1 case in stage II and 3 cases in stage III/IV) were treated with EPOCH...
2024: Leukemia Research Reports
https://read.qxmd.com/read/38515317/the-relationship-between-hematologic-malignancies-on-male-hypogonadism-a-scoping-review
#9
JOURNAL ARTICLE
Bradley Roth, Muhammed A Moukhtar Hammad, Daniel I Sanford, Molly Piper, David W Barham, Faysal A Yafi, Lawrence C Jenkins
INTRODUCTION: The associated symptoms of hypogonadism have been reported in patients with various types of cancer. However, the prevalence and significance of hypogonadism among certain hematologic malignancies have not been completely summarized in recent literature. OBJECTIVE: In this review we aimed to examine the current literature on hypogonadism in patients with hematologic malignancies, with emphasis on leukemias, lymphomas, and multiple myeloma (MM). METHODS: This review included relevant studies published before July 2023 that were retrieved through a search of PubMed using the keywords "hematologic cancer," "hematologic malignancy," blood cancer," "leukemia," "lymphoma," "hypogonadism," "multiple myeloma," and "testosterone...
March 21, 2024: Sexual Medicine Reviews
https://read.qxmd.com/read/38511268/steroid-free-combination-of-5-azacytidine-and-venetoclax-for-the-treatment-of-multiple-myeloma
#10
JOURNAL ARTICLE
Lyndsey Flanagan, Aisling Coughlan, Nicola Cosgrove, Andrew Roe, Yu Wang, Stephanie Gilmore, Izabela Drozdz, Claire Comerford, Jeremy Ryan, Emma Minihane, Salma Parvin, Michael O'Dwyer, John Quinn, Philip Murphy, Simon Furney, Siobhan Glavey, Tríona Ní Chonghaile
Multiple Myeloma (MM) is an incurable plasma cell malignancy, that despite an unprecedented increase in overall survival, lacks truly risk-adapted or targeted treatments. A proportion of patients with MM depend on BCL-2 for survival and recently the BCL-2 antagonist venetoclax has shown clinical efficacy and safety in t(11;14) and BCL-2 overexpressing MM. However, only a small proportion of MM patients rely on BCL-2 (~20%), there is a need to broaden the patient population outside of t(11;14) that can be treated with venetoclax...
March 21, 2024: Haematologica
https://read.qxmd.com/read/38508880/long-term-follow-up-of-the-combination-of-ofatumumab-high-dose-methylprednisolone-and-lenalidomide-for-untreated-chronic-lymphocytic-leukemia-with-biomarker-analysis
#11
JOURNAL ARTICLE
Julio C Chavez, Ariel Grajales, Jose Sandoval-Sus, Elyce Turba, Lisa Nodzon, Angimar Uriepero-Palma, Mohammad Ammad-Ud-Din, Eva Sahakian, Rami Komrokji, Lubomir Sokol, Frederick L Locke, Bijal Shah, Jeffrey Lancet, Eduardo M Sotomayor, Mohamed A Kharfan-Dabaja, Celeste Bello, Javier Pinilla-Ibarz
BACKGROUND: Advancements in frontline therapy and chemotherapy-sparing treatments in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have altered the treatment algorithms of this disease. We present a frontline alternative for treatment- naïve (TN) CLL/SLL patients. METHODS: This was a single-center, phase 2 study of high-dose methylprednisolone (HDMP) and ofatumumab with lenalidomide and ofatumumab consolidative therapy for all comers with TN CLL/SLL...
February 13, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38501758/lymphoplasmacytic-lymphoma-and-multiple-myeloma-coexisting-in-the-same-patient-a-case-series-and-literature-review
#12
JOURNAL ARTICLE
Gilad Itchaki, Osnat Jarhovsky, Jorge J Castillo, Hamza Hassan, Moshe L Gatt, Merav Leiba, Pia Raanani, Morie A Gertz, Iuliana Vaxman
The simultaneous occurrence of Waldenström macroglobulinemia and multiple myeloma in the same patient has been published as case reports. Patients with Waldenström macroglobulinemia often have a small clone of plasma cells. However, the concurrent occurrence of symptomatic myeloma with lytic bone lesions is rare. The diagnosis of this 'hybrid' entity is challenging, and there are no standard therapies. We present six patients from five centers (three in Israel and two in the United States). We describe these patients' unique clinical course and treatment approaches...
March 19, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38497533/an-open-label-phase-2-study-treating-patients-with-first-or-second-relapse-of-multiple-myeloma-with-carfilzomib-pomalidomide-and-dexamethasone-kpd-select-study
#13
JOURNAL ARTICLE
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Oriol, Philippe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios Athanasios Dimopoulos
Once-weekly carfilzomib at 56 mg/m2 plus immunomodulatory drugs and dexamethasone has shown efficacy and tolerability treating early relapsed/refractory multiple myeloma (RRMM). The phase 2 SELECT study (NCT04191616) evaluated efficacy/safety of weekly carfilzomib, pomalidomide, and dexamethasone (KPd) in early RRMM patients refractory to lenalidomide. All 52 treated patients were refractory to prior treatment, and 19 (37%) were triple-class refractory. Overall response rate (ORR; primary endpoint) was 58% (35% ≥ very good partial response, 6% ≥ complete response); median response duration was 20...
March 18, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38493239/beyond-the-marrow-insights-from-comprehensive-next-generation-sequencing-of-extramedullary-multiple-myeloma-tumors
#14
JOURNAL ARTICLE
T Jelinek, D Zihala, T Sevcikova, A Anilkumar Sithara, V Kapustova, H Sahinbegovic, O Venglar, L Muronova, L Broskevicova, S Nenarokov, D Bilek, T Popkova, H Plonkova, J Vrana, V Zidlik, P Hurnik, M Havel, M Hrdinka, Z Chyra, G Stracquadanio, M Simicek, R Hajek
Extramedullary multiple myeloma (EMM) is an aggressive form of multiple myeloma (MM). This study represents the most comprehensive next-generation sequencing analysis of EMM tumors (N = 14) to date, uncovering key molecular features and describing the tumor microenvironment. We observed the co-occurrence of 1q21 gain/amplification and MAPK pathway mutations in 79% of EMM samples, suggesting that these are crucial mutational events in EMM development. We also demonstrated that patients with mutated KRAS and 1q21 gain/amplification at the time of diagnosis have a significantly higher risk of EMM development (HR = 2...
March 16, 2024: Leukemia
https://read.qxmd.com/read/38493059/soho-state-of-the-art-updates-and-next-questions-treatment-evolution-of-mantle-cell-lymphoma-navigating-the-different-entities-and-biological-heterogeneity-of-mantle-cell-lymphoma-in-2024
#15
REVIEW
Andrew Ip, Alexandra Della Pia, Andre H Goy
Progress in mantle cell lymphoma (MCL) has led to significant improvement in outcomes of patients even in the real world (RW) setting albeit to a lesser degree. In parallel to the demonstration of benefit using combination therapy with rituximab plus high-dose cytarabine (R-AraC) as well as dose intensive therapy-autologous stem cell transplantation (DIT-ASCT) consolidation and maintenance, it became clear over the last 2 decades that MCL is a highly heterogenous disease at the molecular level, explaining differences observed in clinical behavior and response to therapy...
February 22, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38490927/port-a-randomized-cross-over-phase-2-study-of-melflufen-peripheral-versus-central-intravenous-administration-in-patients-with-relapsed-refractory-multiple-myeloma
#16
JOURNAL ARTICLE
Ludek Pour, Ilina Micheva, Ganna Usenko, Gabor Mikala, Tamas Masszi, Kameliya Simeonova, Marcus Thuresson, Gunilla Huledal, Stefan Norin, Nicolaas A Bakker, Jiri Minarik
BACKGROUND: Melflufen, a first-in-class alkylating peptide-drug conjugate, rapidly enters tumor cells and metabolizes to melphalan. In previous studies, melflufen was administered via central venous catheter (CVC). However, administration by peripheral venous catheter (PVC) may be preferable. PATIENTS AND METHODS: PORT was a two-period, phase 2 crossover study of CVC versus PVC melflufen administration in patients with relapsed/refractory multiple myeloma. Adults with ≥ 2 prior therapies refractory to/intolerant of an immunomodulatory drug and a proteasome inhibitor were randomized 1:1 to weekly oral dexamethasone plus melflufen (40 mg) via CVC or PVC infusion on day 1 of 28-day cycle 1...
February 23, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38485650/soho-state-of-the-art-updates-and-next-questions-measurable-residual-disease-in-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia
#17
REVIEW
Nicholas J Short, Elias Jabbour, Hagop Kantarjian
Assessment of measurable residual disease (MRD) provides important prognostic information and can inform decision-making about appropriate consolidative therapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Many contemporary treatment protocols for Ph+ ALL achieve high rates of MRD negativity, and several analyses suggest that allogeneic hematopoietic stem cell transplant in first remission can be safely deferred in most patients who achieve MRD negativity by PCR for BCR::ABL1 within 3 months...
February 21, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38481231/health-related-quality-of-life-and-its-determinants-among-cancer-patients-evidence-from-12-148-patients-of-indian-database
#18
JOURNAL ARTICLE
Jyoti Dixit, Nidhi Gupta, Amal Kataki, Partha Roy, Nikita Mehra, Lalit Kumar, Ashish Singh, Pankaj Malhotra, Dharna Gupta, Aarti Goyal, Kavitha Rajsekar, Manjunath Nookala Krishnamurthy, Sudeep Gupta, Shankar Prinja
BACKGROUND: Cancer survivors experience a decrement in health-related quality of life (HRQoL) resulting from the disease as well as adverse effects of therapy. We evaluated the HRQoL of cancer patients, stratified by primary cancer site, stage, treatment response and associated adverse events, along with its determinants. METHODS: Data were collected from 12,148 patients, sampled from seven purposively chosen leading cancer hospitals in India, to elicit HRQoL using the EuroQol questionnaire comprising of 5-dimensions and 5-levels (EQ-5D-5L)...
March 13, 2024: Health and Quality of Life Outcomes
https://read.qxmd.com/read/38479337/expression-of-the-chemokine-receptor-ccr1-decreases-sensitivity-to-bortezomib-in-multiple-myeloma-cell-lines
#19
JOURNAL ARTICLE
Mara N Zeissig, Duncan R Hewett, Krzysztof M Mrozik, Vasilios Panagopoulos, Craig T Wallington-Gates, Andrew Spencer, Sandra M Dold, Monika Engelhardt, Kate Vandyke, Andrew C W Zannettino
BACKGROUND: The proteasome inhibitor bortezomib is one of the primary therapies used for the haematological malignancy multiple myeloma (MM). However, intrinsic or acquired resistance to bortezomib, via mechanisms that are not fully elucidated, is a barrier to successful treatment in many patients. Our previous studies have shown that elevated expression of the chemokine receptor CCR1 in MM plasma cells in newly diagnosed MM patients is associated with poor prognosis. Here, we hypothesised that the poor prognosis conferred by CCR1 expression is, in part, due to a CCR1-mediated decrease in MM plasma cell sensitivity to bortezomib...
March 7, 2024: Leukemia Research
https://read.qxmd.com/read/38468828/car-t-cell-therapy-for-t-cell-malignancies
#20
REVIEW
Ugo Testa, Patrizia Chiusolo, Elvira Pelosi, Germana Castelli, Giuseppe Leone
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes. Thus, six FDA-approved commercial CAR-T cell products that target antigens preferentially expressed on malignant B-cells or plasma cells have been introduced in the therapy of B-cell lymphomas, B-ALLs, and multiple myeloma. These therapeutic successes have triggered the application of CAR-T cell therapy to other hematologic tumors, including T-cell malignancies...
2024: Mediterranean Journal of Hematology and Infectious Diseases
keyword
keyword
68335
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.